173 related articles for article (PubMed ID: 18259682)
1. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.
Brooks DJ; Leinonen M; Kuoppamäki M; Nissinen H
J Neural Transm (Vienna); 2008 Jun; 115(6):843-9. PubMed ID: 18259682
[TBL] [Abstract][Full Text] [Related]
2. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
Destée A; Rérat K; Bourdeix I
Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
[TBL] [Abstract][Full Text] [Related]
3. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
Nissinen H; Kuoppamäki M; Leinonen M; Schapira AH
Eur J Neurol; 2009 Dec; 16(12):1305-11. PubMed ID: 19570145
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.
Reichmann H; Boas J; Macmahon D; Myllyla V; Hakala A; Reinikainen K;
Acta Neurol Scand; 2005 Jan; 111(1):21-8. PubMed ID: 15595934
[TBL] [Abstract][Full Text] [Related]
5. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.
Damier P; Viallet F; Ziegler M; Bourdeix I; Rerat K
Eur J Neurol; 2008 Jul; 15(7):643-8. PubMed ID: 18582341
[TBL] [Abstract][Full Text] [Related]
6. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study.
Onofrj M; Thomas A; Vingerhoets F; Martin W; Giménez-Roldán S; Azulay JP; Bernhard G; Schmidt W; Markabi S
J Neural Transm (Vienna); 2004 Aug; 111(8):1053-63. PubMed ID: 15254793
[TBL] [Abstract][Full Text] [Related]
7. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Brooks DJ; Sagar H;
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
11. Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment.
Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A;
Eur Neurol; 2005; 53(4):197-202. PubMed ID: 15970632
[TBL] [Abstract][Full Text] [Related]
12. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Grandas F; Hernández B;
Eur J Neurol; 2007 Mar; 14(3):282-9. PubMed ID: 17355548
[TBL] [Abstract][Full Text] [Related]
13. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study.
Gershanik O; Emre M; Bernhard G; Sauer D
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):963-71. PubMed ID: 14499313
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
Kuoppamäki M; Leinonen M; Poewe W
J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
[TBL] [Abstract][Full Text] [Related]
16. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.
Ann Neurol; 1997 Nov; 42(5):747-55. PubMed ID: 9392574
[TBL] [Abstract][Full Text] [Related]
17. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Lew MF; Somogyi M; McCague K; Welsh M;
Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
19. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
20. Entacapone. A review of its use in Parkinson's disease.
Holm KJ; Spencer CM
Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]